Purpose
The purpose of this article is to review the evidence for the hypothesis that the core mechanism of Dry Eye Disease (DED) is inflammation, including evidence from recent basic, clinical and translational research involving human patients, animal models, and cell cultures.
Method
Using the key words “dry eye + inflammation” , the authors conducted a comprehensive search of the PubMed and Web of Science databases for scientific articles published in English between January 1st 1900 and August 30th 2013 on the role of inflammation in DED in cell cultures, animal models and humans. The resulting articles were then categorized and reviewed.
Results
The literature search revealed a total of 458 publications, almost all published after 1992. The percentages of original studies and review articles are 77.29% (354) and 22.71% (104), respectively. Among the original studies, the number of reports on inflammation of human DED is 200 (43.7%); animal models, 115 (25.1 %); and cell cultures, 39 (8.5 %). The human DED studies reveal changes of numerous inflammatory cells and mediators in ocular surface and tear film and those changes can be attenuated or reversed by anti-inflammatory drug treatments. The animal DED studies demonstrate that DED is likely a dominant T-lymphocytes, especially T-helper 17-subset (Th17)-mediated autoimmune disease and that the autoimmune-driven inflammatory cycles are fundamentally linked with DED progression. These results are mirrored and confirmed by a number of corneal and conjunctival epithelial cell culture studies that clearly demonstrate an inflammatory immune response pattern when those cells are exposed to desiccation, inflammatory mediators or high osmolarity shock. A yearly distributing plot revealed that 76% were published from 2003 to 2011, 53% from 2008 to 2012, and 11% during the first 9 months of 2013. This distribution signifies a rapidly growing awareness of the importance of inflammation in DED pathogenesis.
Conclusion
The literature review study clearly demonstrate that inflammation is the core mechanism and plays a key role in the pathogenesis of DED as evidenced by research utilizing tissue culture, animal models and subjects with DED. The chronicity of the disease suggests that dysregulation of immune mechanisms leads to a cycle of continued inflammation, accompanied by alterations in both innate and adaptive immune responses. Therefore, developing biomarkers to monitor the ocular surface inflammatory status will not only improve our knowledge to fully understand the mechanisms leading to DED, to better classify the severity of DED, to measure the objective metrics for outcome of treatment, but also provide directions to develop effective and safe anti-inflammatory treatments that will be beneficial for patients with DED.